Author:
Nicolaides Theodore,Horn Biljana,Banerjee Anuradha
Publisher
Springer Berlin Heidelberg
Reference206 articles.
1. Alama A, Barbieri F, Cagnoli M, Schettini G (1997) Antisense oligonucleotides as therapeutic agents. Pharmacological Research 36:171–178
2. Allen JC, Bosl G, Walker R (1985) Chemotherapy trials in recurrent primary intracranial germ cell tumors. Journal of Neurooncology 3:147–152 Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Molecular Car-cinogenesis 20:251–258
3. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Molecular Car-cinogenesis 20:251–258
4. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. Journal of Clinical Oncology 14:1922–1927
5. Balis FM, Holcenberg JS, Blaney SM (2002) General principles of chemotherapy. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, Philadelphia, pp 237–308